Partial splenic embolization plus antitumor therapy for treating patients with hepatocellular carcinoma and splenomegaly: a case series study

PSE combined with interventional and/or systemic therapy shows modest efficacy and a favorable safety profile in patients with HCC and splenomegaly. This approach may reduce the need for prolonged thrombopoietin agonist use and can be conveniently performed concurrently with TACE. Further validation through larger randomized controlled trials is recommended.